Cytomegalovirus

$1M in grants to fund cytomegalovirus vaccine development

Published in Vaccine Weekly, April 7th, 2004

Vical Incorporated (VICL) has received notification of funding of approximately $1 million for research and development related to the company's plasmid DNA vaccine against cytomegalovirus (CMV) under two grants from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH).

A 6-month phase I Small Business Innovation Research (SBIR) grant of approximately $300,000 will partially fund preclinical safety and toxicity evaluation of the CMV vaccine in support of the company's planned phase I human trial.

An 18-month research grant of approximately $700,000 will partially fund novel assays to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-04-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry